Camurus (STO:CAMX) and biopharma group Rhythm today released initial results from an ongoing Phase 1A clinical trial examining the pharmacokinetics and tolerability of an extended-release formulation of setmelanotide.
The drug formulation uses Camurus’ FluidCrystal injection depot drug delivery technology to deliver Setmelanotide, Rhythm’s novel melanocortin-4 receptor agonist designed to treat genetic disorders of obesity.
Read the whole story at our sister site, Drug Delivery Business
The post Rhythm, Camurus tout early data on setmelanotide in rare genetic obesity appeared first on MassDevice.
from MassDevice http://ift.tt/2siQBFO
Cap comentari:
Publica un comentari a l'entrada